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Local activation of costimulatory pathways by e.g. CD40
activation has been shown to generate powerful systemic
anti-tumor responses. Here we report significant anti-
tumor effects obtained with an optimized fully human
agonistic CD40 antibody, ADC-1013, in two syngeneic
tumor models.
An hCD40 transgenic mouse (hCD40tg) strain was used
to evaluate the immune mediated anti-tumor effects of
ADC-1013. Dendritic cells obtained from hCD40tg mice
were hCD40 positive and could be activated by stimulation
with ADC-1013 to a similar extent as human monocyte
derived dendritic cells. Furthermore, stimulation of den-
dritic cells from hCD40tg mice in vitro, with ADC-1013,
induced antigen specific T cell activation.
Two different syngeneic tumor models, hCD40 negative
MB49 bladder cancer and hCD40 positive B16.F10.hCD40
+ melanoma, was used to demonstrate anti-tumor effects.
Subcutaneous tumors from both models were character-
ized by flow cytometry and immunohistochemistry in
hCD40tg mice. Treatment of the bladder cancer model
(MB49) with ADC-1013 resulted in significant anti-tumor
response and long term tumor immunity. The anti-tumor
immunity was shown to be T cell dependent and naïve
mice were protected from tumor challenge by transplanta-
tion of splenocytes from cured hCD40tg mice. In addition,
significant anti-tumor effect was demonstrated in a subcu-
taneous B16.F10.hCD40+ melanoma model.
The human CD40 agonistic antibody ADC-1013 is the
first costimulatory antibody optimized for local immu-
notherapy of cancer. Strong immune mediated anti-tumor
effects were demonstrated. ADC-1013 is currently in late
pre-clinical development.
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